Abstract Data on systemic therapy for metastatic malignant phyllodes tumor (MPT) are limited. To report the clinical characteristics and outcomes of patients with advanced MPT treated at a tertiary care center in North India. We retrospectively analyzed patients with advanced MPT (metastatic or unresectable locally advanced) registered between January 2015 and July 2021. Systemic therapies included ifosfamide plus doxorubicin (IA), single-agent doxorubicin, cisplatin plus etoposide, and pazopanib. Tumor response was assessed radiologically using RECIST version 1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Fourteen patients (median age, 33.5 years) were included; 12 (86%) had metastatic disease. The median follow-up was 19 months. IA achieved a partial response in 4 of 6 (67%) patients, whereas no responses were observed with single-agent doxorubicin, pazopanib, or cisplatin plus etoposide. Median first-line PFS was 3 months overall and 4 months with IA. Median OS was 20 months. IA demonstrated activity in advanced MPT, whereas pazopanib and other regimens showed limited efficacy. Larger studies and multicentric registries are needed due to the rarity of this tumor.
Shrivastava et al. (Wed,) studied this question.